Bioverativ Inc logo

BIVV - Bioverativ Inc Share Price

$104.98 0.3  0.0%

Last Trade - 08/03/18

Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £841.6m
Position in Universe th / 6846
Unlock BIVV Revenue
Relative Strength (%)
1m -1.10%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2012 2013 2014 2015 2016 2017 2018E 2019E CAGR / Avg
0.000 0.000 134.4 560.3 887.4 1,169 1,384 1,456
+304.6 -31.5 +48.0 +9.92
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2017,Bioverativ Inc revenues increased 32% to $1.17B. Net incomebefore extraordinary items decreased 32% to $296.8M.Revenues reflect Domestic segment increase of 31% to$985.1M, Japan segment increase of 31% to $138.8M, Othersegment increase of 61% to $44.6M. Basic Earnings per Shareexcluding Extraordinary Items decreased from $4.07 to$2.75.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


BIVV Revenue Unlock BIVV Revenue

Net Income

BIVV Net Income Unlock BIVV Revenue

Normalised EPS

BIVV Normalised EPS Unlock BIVV Revenue

PE Ratio Range

BIVV PE Ratio Range Unlock BIVV Revenue

Dividend Yield Range

BIVV Dividend Yield Range Unlock BIVV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BIVV EPS Forecasts Unlock BIVV Revenue
Profile Summary

Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN).

Last Annual December 31st, 2017
Last Interim December 31st, 2017
Incorporated August 4, 2016
Public Since January 12, 2017
No. of Shareholders: 663
No. of Employees: 460
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange NASDAQ Global Select Market
Shares in Issue 108,223,644
Free Float (0.0%)
Eligible for
BIVV Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BIVV
Upcoming Events for BIVV
Frequently Asked Questions for Bioverativ Inc
What is the Bioverativ Inc share price?

As of 08/03/18, shares in Bioverativ Inc are trading at $104.98, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Bioverativ Inc share price performed this year?

Shares in Bioverativ Inc are currently trading at $104.98 and the price has moved by 98.6% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bioverativ Inc price has moved by 35.87% over the past year.

What are the analyst and broker recommendations for Bioverativ Inc?

Of the analysts with advisory recommendations for Bioverativ Inc, there are there are currently 0 "buy" , 8 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Bioverativ Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Bioverativ Inc next release its financial results?

Bioverativ Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2018-12-31
What is the Bioverativ Inc dividend yield?

Bioverativ Inc does not currently pay a dividend.

Does Bioverativ Inc pay a dividend?

Bioverativ Inc does not currently pay a dividend.

When does Bioverativ Inc next pay dividends?

Bioverativ Inc does not currently pay a dividend.

How do I buy Bioverativ Inc shares?

To buy shares in Bioverativ Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bioverativ Inc?

Shares in Bioverativ Inc are currently trading at $104.98, giving the company a market capitalisation of £n/a.

Where are Bioverativ Inc shares listed? Where are Bioverativ Inc shares listed?

Here are the trading details for Bioverativ Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BIVV
What kind of share is Bioverativ Inc?

We were not able to load our ranking data for Bioverativ Inc

Is there a Bioverativ Inc share price forecast 2021?

We were not able to load any forecast data for Bioverativ Inc.

How can I tell whether the Bioverativ Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioverativ Inc. Over the past six months, the relative strength of its shares against the market has been 53.95%. At the current price of $104.98, shares in Bioverativ Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bioverativ Inc PE Ratio?

We were not able to find PE ratio data for Bioverativ Inc.

Who are the key directors of Bioverativ Inc?

We were unable to find the directors for Bioverativ Inc.

Who are the major shareholders of Bioverativ Inc?

Here are the top five shareholders of Bioverativ Inc based on the size of their shareholding:

Similar to BIVV
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.